Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532746) titled 'A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies' on April 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Kousai Bio Co., Ltd.
Condition:
Relapsed or Refractory EBV-associated Hematological Malignancies
Intervention:
Biological: KSD-101
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 1, 2026
Target Sample Size: 55
Countries of Recruitment:
China
To know more, visit https:...